Hallgeir Rui, MD, PhD

Interim Co-Director, MCW Cancer Center; WBCS Endowed Professor of Breast Cancer Research; Director, MCW Tissue Bank; Professor and Vice Chair of Research, Pathology

Locations

Pathology & Laboratory Medicine
TBRC

Contact Information

General Interests

Breast Cancer Research

Education

MD, University of Oslo, Oslo, Norway
PhD, Pathology, University of Oslo, Oslo, Norway

Biography

Hallgeir Rui, MD, PhD is internationally recognized for his research on hormone signaling in breast cancer, and has a strong track record of leadership, mentoring and collaboration. He is the WBCS Endowed Professor of Breast Cancer Research at the Medical College of Wisconsin (MCW), with his primary appointment in the Department of Pathology, and a secondary appointment to the Department of Pharmacology & Toxicology. In addition, Dr. Rui serves as the Associate Director of Basic Science and Shared Resources at the MCW Cancer Center. With his past experience as a Program Leader and Shared Resource Director at the NCI-designated Sidney Kimmel Cancer Center at Thomas Jefferson University, Dr. Rui brings valuable experience to the MCW Cancer Center efforts toward NCI-designation. Dr. Rui serves on the Breast Cancer Translational Research Committee of NRG Oncology.

Research Interests

Breast Cancer

Cytokine receptors

Hormones: Estrogen, growth, glucocorticoid, steroid

Endocrinology

Prolactin and Prolactin receptors

Jak2, Stat5, Stat5a, Stat5b

Immunohistochemistry

Pathology

Biomarkers

Early detection

Tissue microarray

Mouse modeling

EGFR, Her2, ErbB2

Functional Blockade of E-Selectin in Tumor-Associated Vessels Enhances Anti-Tumor Effect of Doxorubicin in Breast Cancer.

(Morita Y, Leslie M, Kameyama H, Lokesh GLR, Ichimura N, Davis R, Hills N, Hasan N, Zhang R, Kondo Y, Gorenstein DG, Volk DE, Chervoneva I, Rui H, Tanaka T.) Cancers (Basel). 2020 Mar 19;12(3) PMID: 32204492 03/25/2020
Neuronatin is a modifier of estrogen receptor-positive breast cancer incidence and outcome.

(Plasterer C, Tsaih SW, Peck AR, Chervoneva I, O'Meara C, Sun Y, Lemke A, Murphy D, Smith J, Ran S, Kovatich AJ, Hooke JA, Shriver CD, Hu H, Mitchell EP, Bergom C, Joshi A, Auer P, Prokop J, Rui H, Flister MJ.) Breast Cancer Res Treat. 2019 Aug;177(1):77-91 PMID: 31165373 SCOPUS ID: 2-s2.0-85066986189 06/06/2019
The p52 isoform of SHC1 is a key driver of breast cancer initiation.

(Wright KD, Miller BS, El-Meanawy S, Tsaih SW, Banerjee A, Geurts AM, Sheinin Y, Sun Y, Kalyanaraman B, Rui H, Flister MJ, Sorokin A.) Breast Cancer Res. 2019 06 15;21(1):74 PMID: 31202267 PMCID: PMC6570928 SCOPUS ID: 2-s2.0-85067234098 06/17/2019
Mapping genetic modifiers of radiation-induced cardiotoxicity to rat chromosome 3.

(Schlaak RA, Frei A, Schottstaedt AM, Tsaih SW, Fish BL, Harmann L, Liu Q, Gasperetti T, Medhora M, North PE, Strande JL, Sun Y, Rui H, Flister MJ, Bergom C.) Am J Physiol Heart Circ Physiol. 2019 06 01;316(6):H1267-H1280 PMID: 30848680 PMCID: PMC6620678 SCOPUS ID: 2-s2.0-85066837925 03/09/2019
Identification of a Rat Mammary Tumor Risk Locus That Is Syntenic with the Commonly Amplified 8q12.1 and 8q22.1 Regions in Human Breast Cancer Patients.

(Plasterer C, Tsaih SW, Lemke A, Schilling R, Dwinell M, Rau A, Auer P, Rui H, Flister MJ.) G3 (Bethesda). 2019 05 07;9(5):1739-1743 PMID: 30914425 PMCID: PMC6505137 SCOPUS ID: 2-s2.0-85065792535 03/28/2019
An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles.

(Ortiz A, Gui J, Zahedi F, Yu P, Cho C, Bhattacharya S, Carbone CJ, Yu Q, Katlinski KV, Katlinskaya YV, Handa S, Haas V, Volk SW, Brice AK, Wals K, Matheson NJ, Antrobus R, Ludwig S, Whiteside TL, Sander C, Tarhini AA, Kirkwood JM, Lehner PJ, Guo W, Rui H, Minn AJ, Koumenis C, Diehl JA, Fuchs SY.) Cancer Cell. 2019 01 14;35(1):33-45.e6 PMID: 30645975 PMCID: PMC6336114 SCOPUS ID: 2-s2.0-85058438732 01/16/2019
Mapping Mammary Tumor Traits in the Rat.

(Flister MJ, Joshi A, Bergom C, Rui H.) Methods Mol Biol. 2019;2018:249-267 PMID: 31228161 SCOPUS ID: 2-s2.0-85068143262 06/23/2019
Exploring drivers of gene expression in the Cancer Genome Atlas.

(Rau A, Flister M, Rui H, Auer PL.) Bioinformatics. 2019 01 01;35(1):62-68 PMID: 30561551 PMCID: PMC6298045 SCOPUS ID: 2-s2.0-85058741070 12/19/2018
Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling.

(Tran TH, Utama FE, Sato T, Peck AR, Langenheim JF, Udhane SS, Sun Y, Liu C, Girondo MA, Kovatich AJ, Hooke JA, Shriver CD, Hu H, Palazzo JP, Bibbo M, Auer PW, Flister MJ, Hyslop T, Mitchell EP, Chervoneva I, Rui H.) Clin Cancer Res. 2018 12 15;24(24):6355-6366 PMID: 30097435 SCOPUS ID: 2-s2.0-85058487046 08/12/2018
Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells.

(Gennaro VJ, Stanek TJ, Peck AR, Sun Y, Wang F, Qie S, Knudsen KE, Rui H, Butt T, Diehl JA, McMahon SB.) Proc Natl Acad Sci U S A. 2018 10 02;115(40):E9298-E9307 PMID: 30224477 PMCID: PMC6176615 SCOPUS ID: 2-s2.0-85054360749 09/19/2018
CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion.

(Jiao X, Velasco-Velázquez MA, Wang M, Li Z, Rui H, Peck AR, Korkola JE, Chen X, Xu S, DuHadaway JB, Guerrero-Rodriguez S, Addya S, Sicoli D, Mu Z, Zhang G, Stucky A, Zhang X, Cristofanilli M, Fatatis A, Gray JW, Zhong JF, Prendergast GC, Pestell RG.) Cancer Res. 2018 04 01;78(7):1657-1671 PMID: 29358169 PMCID: PMC6331183 SCOPUS ID: 2-s2.0-85047155981 01/24/2018
Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth.

(Pestell TG, Jiao X, Kumar M, Peck AR, Prisco M, Deng S, Li Z, Ertel A, Casimiro MC, Ju X, Di Rocco A, Di Sante G, Katiyar S, Shupp A, Lisanti MP, Jain P, Wu K, Rui H, Hooper DC, Yu Z, Goldman AR, Speicher DW, Laury-Kleintop L, Pestell RG.) Oncotarget. 2017 Oct 10;8(47):81754-81775 PMID: 29137220 PMCID: PMC5669846 11/16/2017

Hallgeir Rui, MD, PhD